Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
He discusses learnings about durability, dosing, biomarkers, and more for this first-in-class target.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.